Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Sanofi-Aventis Ends PDI Sales Contract

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Big pharma is “reevaluating its commercial model,” PDI said in reaction to losing the $18 mil. to $20 mil. Sanofi contract.

You may also be interested in...



AstraZeneca To Cut 3,000 Jobs As It Seeks To Rationalize Production Assets

CEO David Brennan tells investors the decision is another step in the company’s program to increase efficiencies.

AstraZeneca To Cut 3,000 Jobs As It Seeks To Rationalize Production Assets

CEO David Brennan tells investors the decision is another step in the company’s program to increase efficiencies.

PDI Wants To Help Small Pharma Develop Products In-House

Contract sales provider wants to diversify into small pharma services as big pharma cuts back outsourced sales reps.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS063267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By